Maxim Group Maintains Buy on Zevra Therapeutics, Raises Price Target to $35
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Maxim Group analyst Jason McCarthy maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $25 to $35.
Maxim Group analyst Jason McCarthy maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $25 to $35.